todays stock market news and analysis  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  stock market news todays stock market news  analysis facebooks  profitability will be even better than expected by motley fool investors were particularly encouraged by the companys outlook for expenses this year  etfs to keep you invested after retirement by motley fool etfs offer diversification income and growth at a low cost never again big oil is back and practicing caution by oilpricecom oil majors are coming around to the idea that oil prices will remain depressed for the foreseeable future  value stocks for wise investors by motley fool a look at  overlooked stocks latest news videos cramer on how to understand market  why is netflix taking out a  mi cramers exec cut ceos tell cramer cramer explains the key to understa latest news why bojangles inc stock dropped today   pm  motley fool appears in stocks weatherford wft q loss in line revenues lag   pm  zackscom appears in investing ideas yandex loses market share in spite of strong growth   pm  motley fool appears in stocks  things introverts need to explain to their managers   pm  motley fool appears in stocks update north korea tests another icbm putting us cities in range   pm  reuters appears in stocks are uk voters still supporting brexit   pm  global traders association appears in politics chipotle mexican grill inc solid q results show investor fears are misplaced   pm  motley fool appears in stocks charter communications inc jumped on earnings what you need to know   pm  motley fool appears in stocks this week in solar   pm  motley fool appears in stocks the real strategy behind nvidia’s geforce now gaming service   pm  motley fool appears in stocks mccain pulls the plug on obamacare skinny repeal without replacement   pm  motley fool appears in stocks sprint proposes merger with charter communications  wsj   pm  reuters appears in world markets ssc technologies touches new highs after a solid quarterly win   pm  motley fool appears in stocks forget costco these  stocks have doubled this year   pm  motley fool appears in stocks interviewchiles antofagasta very keen to move forward on investment plans   pm  reuters appears in politics oil  gas stock roundup earnings and ma sent these stocks soaring   pm  motley fool appears in stocks energy recap a look at the latest opec meeting   pm  seekingalpha appears in stocks bitcoin price analysis with august st looming uncertainty is the only certainty   pm  bitcoin magazine appears in bitcoin union cheers as trucks kept out of us selfdriving legislation   pm  reuters appears in stocks tobacco bond prices weaker after us proposes cigarette nicotine cut   pm  reuters appears in fundamental analysis view more headlines browse news by category etfs when it comes to smart beta etfs there is no right or wrong bond etf segment has more room to grow formerly dumped on trump mexico etf now a darling more etfs technology comcastbacked virtual reality startup altspacevr shuts down how facebook’s move to video will fundamentally change its business apple discontinues ipod shuffle and nano more technology commodities wheaton precious metals shares cross above  dma ego stock crowded with sellers technology sector update for  moblatenmstr more commodities investing ideas weatherford wft q loss in line revenues lag us telecom price competition to intensify busy week ahead will dollar hit fresh multiyear lows more investing ideas market intelligence stay ahead of the markets with these mustread articles d printing is quietly thriving without mainstream adoption trevir nath nasdaq ndaq nd quarter profit surges more than twofold richard saintvilus an indepth look at baidus bidu artificial intelligence aspirations prableen bajpai stock market today stocks to watch why chevrons earnings werent as bad as they looked featured story from latest articles by martin tillier martin tillers new mustread column on the markets enlightening entertaining every day only at nasdaqcom the case for  beleaguered oilfield service stocks   am earnings confirm facebook is better investment than twitter   am eli lilly llys seemingly illogical reaction to earnings beat   am week ahead earnings highlights   am dont count opec out yet   am more martin tillier closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex jeffrey s hatfield executive profile  biography  bloomberg july    pm et capital markets company overview of atlas venture lp snapshotpeople  overviewboard memberscommittees executive profile jeffrey s hatfield atlas advisor atlas venture lpagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr jeffrey s hatfield also known as jeff is an atlas advisor of atlas venture lp mr hatfield was entrepreneurinresidence venture partner and advisor at the firm mr hatfield served as the chief executive officer and president of vitae pharmaceuticals inc from march  to october   mr hatfield was nearly twenty years with bristolmyers squibb company served as senior vice president of bristolmyers s virology and immunology division where he  was responsible for all aspects of the  billion business his career also included responsibilities as president and general manager of bmscanada vice president of us managed health care for bms and a variety of marketing sales and general management positions at bms he was directly associated with several product successes including pravachol® plavix® avapro® abilify® reyataz® and atripla® mr hatfield was responsible for sales marketing policy and medical strategy within the hiv hepatitis and ra therapeutic categories he has been independent director at atyr pharma inc since april   mr hatfield has been a director of invivo therapeutics holdings corp since november   he serves as a director of the biotechnology industry organization bio he served as a director of vitae pharmaceuticals inc from march  to october   he served as a director of ambit biosciences corporation from june   to november   he was an adjunct professor at purdue university he is on faculty of drexel universityslebow college of business and the chapmankgi school of biopharmacy he studied bachelor of science degree in pharmacy from purdue universitys school of pharmacy and a master of business administration degree from the wharton school at the university of pennsylvaniaread full background corporate headquarters  technology squarecambridge massachusetts united statesphone fax  board members memberships presentdirectorinvivo therapeutics holdings corppresentindependent directoratyr pharma inc education mba university of pennsylvania  the wharton schoolbs school of pharmacy purdue university other affiliations ambit biosciences corporationvitae pharmaceuticals incuniversity of pennsylvania  the wharton schoolatyr pharma incschool of pharmacy purdue universityinvivo therapeutics holdings corp annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact atlas venture lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close distinguished alumni  jeffrey s hatfield skip to page content college of pharmacyoffice of advancement website directory topicarea navigation links advancement welcome stewardship types of gifts how to give giving clubs planned giving corporate partners annual reports tax information contact information alumni  friends welcome giving news  events resources class reunions recognition  awards pharmacy alumni association class notesaddress updates contact information honors  awards overview deans certificate of achievement dr aziz teaching awards professor henry heine award distinguished alumni awards friends of pharmacy awards honorary doctorates lifetime achievement awards glen j sperandio award tyler lecturers eaton entrepreneur of the year award research and scholarship achievement award publications welcome the purdue pharmacist magazine mortar  pestle enewsletter program dataannual reports class notesaddress updates contact information engagement overview deans advisory council minority advocacy council staff home prospective students prospective students navigation links becoming a pharmacist careers responsibilities qualifications education preparation student performance and career opportunities offcampus students graduate students office of student services office of multicultural programs student organizations financial literacy resources pharmacy continuing education current students current students navigation links main current courses exam dates for core courses calendar for pharmd program student handbook academic standards health library access blackboard learn mypurdue office of student services office of multicultural programs student organizations financial literacy resources online registration information faculty and staff faculty and staff navigation links faculty and staff directory list of resources college of pharmacy policies faculty meeting minutes college sharepoint site pharmd assessment plan purdue policies and procedures business office staff advisory council health library access onepurdue portal mypurdue human resources benefits center for healthy living leadership organizations professional development alumni and friends alumni and friends navigation links welcome class notesaddress update giving news  events resources class reunions recognition and awards pharmacy alumni association the purdue pharmacist magazine contact information   giving distinguished alumni  jeffrey s hatfield jeffrey s hatfield ceo vitae pharmaceuticals inc jeff hatfield was born and raised in indianapolis  he received his bs degree from purdue university’s school of pharmacy in   while at purdue his passion for blending science and business emerged as a lifelong career goal  working with dr ken kirk head of purdue’s phad department at the time jeff pursued a uniquely designed curriculum that supplemented the core pharmacy program and work as a teaching assistant in clinical pharmacy with extensive elective coursework at the krannert school of management  while in the program mr hatfield wrote a threestage plan that became the blueprint for the next  years of his career after graduating from purdue mr hatfield began work as a pharmacist for revco drug stores in southern indiana  the following year he was promoted to chief pharmacist  store manager in martinsville becoming revco’s youngest store manager  working double shifts for the better part of the next two and a half years he earned enough money to continue on to the next stage of his plan pursuing an advanced degree in business  in  mr hatfield was accepted into the master’s program at the university of pennsylvania’s wharton school of business where he completed his mba in  after graduation mr hatfield entered the third stage of his plan beginning work at squibb now bristolmyers squibb as an analyst and business consultant to the central us business unit  from there he progressed through a variety of field and corporate positions ultimately gaining responsibility for the eastern quarter of the us  in  mr hatfield was put in charge of bms’s us managed health care business responsible for negotiating and contracting over  billion of product sales through the full array of managed care entities including hmos insurers pbms and state and federal government agencies in  mr hatfield became president of bms canada where he was responsible for all aspects of the company’s three core business units  branded products generics and hospital products  during his tenure in canada the company enjoyed strong performance including success with several product launches that achieved sales and market share significantly above global standards  mr hatfield also took a leadership role with the pharma industry’s trade organization the pharmaceutical manufacturer’s association of canada pmac where he first served as board member then treasurer and eventually vice chairman  in his role with pmac mr hatfield worked directly with the canadian government on regulatory access reimbursement and other policy issues  in  bmscanada was recognized as the ‘most admired company’ in the province of quebec in  mr hatfield returned to the us as head of bms’s virology and immunology divisions  while in that role he redefined the divisions’ clinical operational and financial strategies acquired and merged dupont’s virology business and launched blockbuster reyataz® to the market  most significantly mr hatfield conceptualized and negotiated an initiative with the primary competitor company gilead pharmaceuticals to better serve the needs of people living with hiv by creating the industry’s first “onepill onceaday” complete hiv drug regimen  the product atripla® now generates over  billion in annual sales in  mr hatfield left the security of large pharma to enter the entrepreneurial world of biotech as president and ceo of vitae pharmaceuticals a privately held venturebacked biotech research company focused on novel approaches to rational structurebased drug discovery  since joining vitae mr hatfield has grown his company from an intriguing platform technology startup into a highly productive clinicalstage drug discovery and development engine  vitae currently is advancing a robust pipeline of internally discovered assets in large therapeutic areas with high unmet medical need including chronic kidney disease diabetes alzheimer’s disease and atherosclerosis  vitae’s lead program vtp is advancing towards phase iib clinical trials on an accelerated biomarkerbased registration path negotiated with fda vitae was recently recognized as one of pennsylvania’s ‘top  best places to work’   among all pa industries  companies  vitae also was recognized by the trade publication the scientist as a life sciences ‘best place to work’ with a  ranking among all life science companies  further mr hatfield has been recognized in ernst  young’s annual entrepreneur of the year contest and last year was a philadelphia area life science ceo of the year mr hatfield currently serves on the board of directors of vitae pharmaceuticals and the board of the biotechnology industry organization bio the biotech industry’s national policy organization  he is also an advisor and visiting lecturer for purdue university’s school of pharmacy and advisor to drexel university’s lebow college of business mr hatfield is married to janet who works for a global wound care and ostomy company in princeton nj  he has two sons ages  and   steven is a social worker and brian is completing his master’s in medicine at boston university  in his down time jeff enjoys competitive cycling racquetball and golf email webmaster maintained by college of pharmacy this page was last modified at  am on july   purdue university college of pharmacy  stadium mall drive west lafayette in     fax     purdue university  an equal accessequal opportunity university  copyright complaints if you have trouble accessing this page because of a disability please contact us at webmasterpharmacypurdueedu atyr pharma announces appointment of jeffery s hatfield to its board of directors  the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases atyr pharma announces appointment of jeffery s hatfield to its board of directors apr   am edt san diego april   prnewswire  atyr pharma inc nasdaq life a biotherapeutics company engaged in the discovery and development of physiocrinebased therapeutics to address severe rare diseases today announced the appointment of mr jeffrey s hatfield as an independent board director to atyr pharmas board of directors effective immediately mr hatfield brings relevant industry operations experience and expertise to atyr at an important and exciting time for atyrs growth jeffrey s hatfield served as president chief executive officer of vitae pharmaceuticals from march  through october  when vitae was acquired by allergan plc during his tenure at vitae mr hatfield focused the company on high value therapeutic areas with significant global unmet medical need including autoimmune disorders diabetes immunooncology and more atyr has potentially elucidated new immunological pathways as innovative therapeutic intervention points for patients said mr hatfield there is tremendous opportunity for improving patients lives by leveraging multiple therapeutic modalities based on their physiocrine biology we are humbled to attract such an accomplished biotech executive to our board to help support our mission to develop new immunological pathways for the betterment of patients said john mendlein phd ceo jeff is a valuable addition to our board as we continue to grow and tap into his strategic operational expertise from running vitae which also had novel programs in immunology about jeffrey s hatfield jeffrey s hatfield most recently served as president chief executive officer and a member of the board of directors of vitae pharmaceuticals from  to  as ceo mr hatfield successfully transitioned vitae from a novel platform technology startup to a thriving productfocused company with a robust pipeline of multiple firstinclass clinical stage and preclinical stage assets generated from the companys internal discovery engine  mr hatfield took the company public in  and in october  vitae pharmaceuticals was acquired by allergan plc for approximately  million in cash prior to joining vitae pharmaceuticals mr hatfield worked at bristolmyers squibb in a variety of executive positions including senior vice president of bmss immunology and virology divisions where he was responsible for all aspects of the  billion business president and general manager canada and vice president us managed health care while at bms mr hatfield was directly associated with several product successes including pravachol® plavix® avapro® abilify® reyataz® and atripla® mr hatfield holds an mba from the wharton school university of pennsylvania and a bachelors degree in pharmacy from purdue university he previously served as a board member of ambit biosciences before its acquisition by daiichisankyo and as a member of the board of directors of the biotechnology industry organization bio serving on the executive committee of the emerging company section  mr hatfield currently serves as a board member of invivo therapeutics a biotechnology company and as a member of the advisory committees for purdue universitys college of pharmacy where he is a distinguished alumni and is on faculty drexel universitys lebow college of business and the chapmankgi school of biopharmacy about atyr pharma atyr pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology a newly discovered set of physiological pathways to date the company has generated three innovative therapeutic candidate programs based on its knowledge of physiocrine biology in three different therapeutic areas atyr has built an intellectual property estate to protect its pipeline comprising over  issued patents or allowed patent applications that are owned or exclusively licensed including over  potential physiocrinebased protein compositions atyrs key programs are currently focused on severe rare diseases characterized by immune imbalance for which there are currently limited or no treatment options for more information please visit httpwwwatyrpharmacom forwardlooking statements this press release contains forwardlooking statements within the meaning of the private litigation reform act  forwardlooking statements are usually identified by the use of words such as anticipates believes estimates expects intends may plans projects seeks should will and variations of such words or similar expressions we intend these forwardlooking statements to be covered by such safe harbor provisions for forwardlooking statements and are making this statement for purposes of complying with those safe harbor provisions these forwardlooking statements including statements regarding the potential of resolaris™ or stalaris™ the ability of the company to undertake certain development activities such as clinical trial enrollment and the conduct of clinical trials and accomplish certain development goals the timing of initiation of additional clinical trials and of reporting results from our clinical trials and reflect our current views about our plans intentions expectations strategies and prospects which are based on the information currently available to us and on assumptions we have made although we believe that our plans intentions expectations strategies and prospects as reflected in or suggested by those forwardlooking statements are reasonable we can give no assurance that the plans intentions expectations or strategies will be attained or achieved furthermore actual results may differ materially from those described in the forwardlooking statements and will be affected by a variety of risks and factors that are beyond our control including without limitation risks associated with the discovery development and regulation of our physiocrinebased product candidates as well as those set forth in our most recent annual report on form k for the year ended december   and in our other sec filings except as required by law we assume no obligation to update publicly any forwardlooking statements whether as a result of new information future events or otherwise   contact mark johnson sr director investor relations mjohnsonatyrpharmacom  to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesatyrpharmaannouncesappointmentofjefferyshatfieldtoitsboardofdirectorshtml source atyr pharma inc the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more jeffrey s hatfield  advisor at atlas venture inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink jeffrey s hatfield advisor at atlas venture inc overview in the news relationships paths education career history boards  committees political donations investments transactions jeffrey s hatfield advisor at atlas venture inc overview age  born  notable companies bristol myers international group vitae pharmaceuticals inc board seats  number of relationships this person is connected to  people in the news see more relsci october   jeffrey s hatfield is no longer serving in their position at vitae pharmaceuticals inc globenewswire august   vitae pharmaceuticals appoints scott applebaum as general counsel and corporate secretary globenewswire august   vitae pharmaceuticals reports second quarter  operating and financial results globenewswire june   vitae pharmaceuticals announces appointment of carole sable md as chief medical officer globenewswire november   vitae pharmaceuticals to present at th annual piper jaffray healthcare conference see full news coverage and complete stories with relsci professional create your news feed see more relationships see details mark d perrin chief executive officer  chairman of the board at invivo therapeutics holdings corp john d mendlein chief executive officer  director at atyr pharma inc faheem hasnain former president chief executive officer  director at pdl biopharma inc paul schimmel cofounder at alnylam pharmaceuticals inc kenneth dipietro limited partner at lead edge capital management llc perry karsen venture partner at third rock ventures llc david e i pyott director at edwards lifesciences llc daniel m junius former director at immunogen inc john f crowley chief executive officer at amicus therapeutics inc daniel r marshak senior vice president  chief scientific officer at perion network ltd see  more listings with relsci professional start my free trial ➤ see  more paths to jeffrey s hatfield jeffrey s hatfield you connections via relationship science jeffrey s hatfield sync your contacts to see how you can connect with jeffrey s hatfield start my free trial ➤ see more educational background bachelors degree in pharmacy  purdue university purdue university located in west lafayette indiana is the flagship university of the sixcampus purdue university system purdue was founded on may   as a landgrant university when the indiana general assembly taking advantage of the morrill act accepted a donation of land and money from lafayette businessman john purdue to establish a college of science technology and agriculture in his name the first classes were held on september   with six instructors and  students the university was founded with the gift of  from john purdue a lafayette business leader and philanthropist along with  from tippecanoe county and  acres  km² of land from lafayette residents in support of the project in  it was decided that the new school would be built near the city of lafayette and established as purdue university in the name of the institution’s principal benefactor the west lafayette campus offers more than  majors for undergraduates over  master’s and doctoral programs and professional degrees in pharmacy and veterinary medicine in addition purdue has  intercollegiate sports teams and more than  student organizations today purdue is a member of the big ten conference purdue enrolls the second largest student body of any university in indiana as well as the fourth largest international student population of any university in the united states mba  university of pennsylvania  the wharton school the wharton school is the business school of the university of pennsylvania an ivy league university in philadelphia pennsylvania wharton was the world’s first collegiate business school and the first business school in the united states it was established in  through a donation of joseph wharton career history advisor current atlas venture inc atlas venture focuses on investments in earlystage companies in the communications information technology and life sciences sectors the firm invests primarily in companies located in the us and europe they seek to identify innovative companies that have the potential to change the structure of markets atlas venture looks for agile scalable and defensible businesses the firm seeks to partner with international teams that are experienced in the increasing globalization of emerging technology and life sciences companies through their combined focus on technology and the life sciences atlas venture seeks to exploit opportunities that bridge the gap between the two sectors within the technology sector the firm targets companies involved in components systems software and services their life sciences investments focus on companies involved in pharmaceuticals drug discovery and medical devicesatlas venture is typically the lead investor in their portfolio companies the firm takes significant stakes in seed and earlystage businesses with extraordinary talent visionary leadership and proprietary assets they also invest in select latestage opportunities investments generally range from  million to  million over the life of the company vice president us tenure unconfirmed managed health care associates inc managed health care associates inc provides management and information technology support services to the healthcare industry it operates as a health care services and technology company that offers a portfolio of services and solutions to support the diverse and complex needs of the alternate site health care providers the firm specializes in group purchasing managed care and payer contracting reimbursement management specialty pharmacy solutions pharmaceutical data analytics consultant pharmacy software and legislative advocacy services the company was founded in  and is headquartered in florham park nj president chief executive officer  director    vitae pharmaceuticals inc vitae pharmaceuticals inc is a clinicalstage biopharmaceutical company its focus is on discovering and developing novel small molecule drugs for diseases including chronic kidney disease diabetes and alzheimers disease and autoimmune disorders acute coronary syndrome and immunooncology the company was founded by john j baldwin bartosz a grzybowski george m whitesides and eugene shakhnovich on may   and is headquartered in fort washington pa president  general manager prior bristol myers international group senior vice presidentvirology  immunology divisions prior bristolmyers squibb company bristolmyers squibb company our company has a strong legacy of innovation that began in new york in  when edward r squibb md founded a pharmaceutical company in brooklyn and in  when two friends william mclaren bristol and john ripley myers purchased a struggling drug manufacturing firm in clinton together they laid the foundation for our company today — a global biopharma leader that continues this legacy of innovation boards  committees corporate boards ▾ member board of directors   current atyr pharma inc atyr pharma inc develops protein therapeutics and novel class of biologic drugs it plans to build a pipeline of innovative therapeutic products based on physiocrine biology the company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics atyr pharma was founded by paul schimmel xianglei yang and bruce beutler in  and is headquartered in san diego ca director   current invivo therapeutics holdings corp invivo therapeutics holdings corp operates as a research and clinicalstage biotechnology company which focuses on the treatment of spinal cord injuries its treatment approach is the neurospinal scaffold implant which is designed for implantation at the site of injury within a spinal cord and is intended to treat acute sci the company was founded by joseph p vacanti frank m reynolds and robert langer on november   and is headquartered in cambridge ma director current invivo therapeutics corp invivo therapeutics corp operates as a medical device company that develops groundbreaking technologies for the treatment of spinal cord injuries the company was founded by joseph p vacanti and robert s langer jr in  and is headquartered in cambridge ma director    ambit biosciences corp ambit biosciences corp develops pharmaceutical drugs it engages in discovery development and commercialization of smallmolecule kinase inhibitors for the treatment of cancer the firm provides drug to treat unmet medical needs in oncology autoimmune and inflammatory diseases the company was founded on may   and is headquartered in san diego ca president chief executive officer  director    vitae pharmaceuticals inc vitae pharmaceuticals inc is a clinicalstage biopharmaceutical company its focus is on discovering and developing novel small molecule drugs for diseases including chronic kidney disease diabetes and alzheimers disease and autoimmune disorders acute coronary syndrome and immunooncology the company was founded by john j baldwin bartosz a grzybowski george m whitesides and eugene shakhnovich on may   and is headquartered in fort washington pa nonprofit boards ▾ member emerging companies section governing board   current biotechnology innovation organization biotechnology innovation organization is the worlds biotechnology organization providing advocacy business development and communications services for more than  members worldwide bio members are involved in the research and development of innovative healthcare agricultural industrial and environmental biotechnology technologies corporate members range from entrepreneurial companies developing a first product to fortune  multinationals also represent state and regional biotech associations service providers to the industry and academic centers member advisory committee current purdue university purdue university located in west lafayette indiana is the flagship university of the sixcampus purdue university system purdue was founded on may   as a landgrant university when the indiana general assembly taking advantage of the morrill act accepted a donation of land and money from lafayette businessman john purdue to establish a college of science technology and agriculture in his name the first classes were held on september   with six instructors and  students the university was founded with the gift of  from john purdue a lafayette business leader and philanthropist along with  from tippecanoe county and  acres  km² of land from lafayette residents in support of the project in  it was decided that the new school would be built near the city of lafayette and established as purdue university in the name of the institution’s principal benefactor the west lafayette campus offers more than  majors for undergraduates over  master’s and doctoral programs and professional degrees in pharmacy and veterinary medicine in addition purdue has  intercollegiate sports teams and more than  student organizations today purdue is a member of the big ten conference purdue enrolls the second largest student body of any university in indiana as well as the fourth largest international student population of any university in the united states member advisory committee current chapman university the mission of chapman university is to provide personalized education of distinction that leads to inquiring ethical and productive lives as global citizens member advisory committee current drexel university  lebow college of business bennett s lebow college of business is a school political donations   jim gerlach president  chief executive officer at business industry political action committee   robert menendez senator from new jersey investments details hidden vitae pharmaceuticals inc vitae pharmaceuticals inc is a clinicalstage biopharmaceutical company its focus is on discovering and developing novel small molecule drugs for diseases including chronic kidney disease diabetes and alzheimers disease and autoimmune disorders acute coronary syndrome and immunooncology the company was founded by john j baldwin bartosz a grzybowski george m whitesides and eugene shakhnovich on may   and is headquartered in fort washington pa transactions details hidden vitae pharmaceuticals inc raised money in a private placement transaction other affiliations jeffrey s hatfield is affiliated with atlas venture inc managed health care associates inc vitae pharmaceuticals inc bristol myers international group bristolmyers squibb company atyr pharma inc invivo therapeutics holdings corp invivo therapeutics corp ambit biosciences corp vitae pharmaceuticals inc biotechnology innovation organization purdue university chapman university drexel university  lebow college of business youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ jeffrey s hatfield president and ceo vitae pharmaceuticals timesjavascript is disabled market profiles login sign up login sign up   edit person jeffrey s hatfield president and ceo at vitae pharmaceuticals location philadelphia pa add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop jeffrey s hatfield president and ceo at vitae pharmaceuticals location philadelphia pa add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop jeff hatfield joined vitae pharmaceuticals as president chief executive officer and a member of the board of directors in march  since becoming ceo he has successfully transitioned vitae from a novel technology startup to a thriving productfocused discovery and development engine with a robust pipeline that includes multiple programs advancing in human clinical trials mr hatfield has focused the company on high value therapeutic areas with significant global unmet medical need including kidney disease diabetes alzheimer’s disease and atherosclerosis notably since joining the company mr hatfield has grown shareholder value in a uniquely capital efficient way – vitae’s last venture round dates back to  his first year with the company prior to joining vitae pharmaceuticals mr hatfield worked at bristolmyers squibb in a variety of executive positions including senior vice president of bms’s virology and immunology divisions where he was responsible for all aspects of the  billion business president and general manager canada and vice president us managed health care while at bms mr hatfield was directly associated with several product successes including pravachol® plavix® avapro® abilify® reyataz® and atripla® mr hatfield holds an mba from the wharton school university of pennsylvania and a bachelor’s degree in pharmacy from purdue university where he is a distinguished alumni he is a member of the board of directors of the biotechnology industry organization bio serving on the emerging company section and the capital formation and intellectual property committees he is also a member of the advisory committees for purdue university’s college of pharmacy drexel university’s lebow college of business and the chapmankgi school of biopharmacy  companies in career na related markets  colleagues na related investments alias na industry pharmaceutical and medicine manufacturing tags na topics of influence web site na careers achievements investments related people edit view all jeffrey s hatfieldcareer  jun ambit biosciences board member mar vitae pharmaceuticals president and ceo oct to mar bristolmyers squibb svp virology and immunology jan to oct bristolmyers squibb president and general manager canada competencies edit view all jeffrey s hatfieldeducation   university of pennsylvania  the wharton school business administration purdue university pharmacy edit jeffrey s hatfieldachievements and recognitions add milestone no milestones has been recorded for jeffrey s hatfield edit jeffrey s hatfieldlinks add link no links has been recorded for jeffrey s hatfield jeffrey s hatfieldinvestmentsacquisitions no investments has been recorded for jeffrey s hatfield jeffrey s hatfieldinvestments representing others no investment reps has been recorded for jeffrey s hatfield jeffrey s hatfieldrelated people colleagues at vitae pharmaceuticals scott applebaum general counsel and corporate secretary aug carole sable chief medical officer jun jeffrey s hatfield president  chief executive officer mar richard gregg chief scientific officer view all jeffrey s hatfieldrecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies atyr pharma announces appointment of jeffery s hatfield to its board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballatyr pharma announces appointment of jeffery s hatfield to its board of directorspr newswireapril  reblogsharetweetsharesan diego april   prnewswire  atyr pharma inc life a biotherapeutics company engaged in the discovery and development of physiocrinebased therapeutics to address severe rare diseases today announced the appointment of mr jeffrey s hatfield as an independent board director to atyr pharmas board of directors effective immediately mr hatfield brings relevant industry operations experience and expertise to atyr at an important and exciting time for atyrs growthjeffrey s hatfield served as president chief executive officer of vitae pharmaceuticals from march  through october  when vitae was acquired by allergan plc during his tenure at vitae mr hatfield focused the company on high value therapeutic areas with significant global unmet medical need including autoimmune disorders diabetes immunooncology and moreatyr has potentially elucidated new immunological pathways as innovative therapeutic intervention points for patients said mr hatfield there is tremendous opportunity for improving patients lives by leveraging multiple therapeutic modalities based on their physiocrine biologywe are humbled to attract such an accomplished biotech executive to our board to help support our mission to develop new immunological pathways for the betterment of patients said john mendlein phd ceo jeff is a valuable addition to our board as we continue to grow and tap into his strategic operational expertise from running vitae which also had novel programs in immunologyabout jeffrey s hatfieldjeffrey s hatfield most recently served as president chief executive officer and a member of the board of directors of vitae pharmaceuticals from  to  as ceo mr hatfield successfully transitioned vitae from a novel platform technology startup to a thriving productfocused company with a robust pipeline of multiple firstinclass clinical stage and preclinical stage assets generated from the companys internal discovery engine  mr hatfield took the company public in  and in october  vitae pharmaceuticals was acquired by allergan plc for approximately  million in cash prior to joining vitae pharmaceuticals mr hatfield worked at bristolmyers squibb in a variety of executive positions including senior vice president of bmss immunology and virology divisions where he was responsible for all aspects of the  billion business president and general manager canada and vice president us managed health care while at bms mr hatfield was directly associated with several product successes including pravachol® plavix® avapro® abilify® reyataz® and atripla® mr hatfield holds an mba from the wharton school university of pennsylvania and a bachelors degree in pharmacy from purdue university he previously served as a board member of ambit biosciences before its acquisition by daiichisankyo and as a member of the board of directors of the biotechnology industry organization bio serving on the executive committee of the emerging company section  mr hatfield currently serves as a board member of invivo therapeutics a biotechnology company and as a member of the advisory committees for purdue universitys college of pharmacy where he is a distinguished alumni and is on faculty drexel universitys lebow college of business and the chapmankgi school of biopharmacyread moreabout atyr pharmaatyr pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology a newly discovered set of physiological pathways to date the company has generated three innovative therapeutic candidate programs based on its knowledge of physiocrine biology in three different therapeutic areas atyr has built an intellectual property estate to protect its pipeline comprising over  issued patents or allowed patent applications that are owned or exclusively licensed including over  potential physiocrinebased protein compositions atyrs key programs are currently focused on severe rare diseases characterized by immune imbalance for which there are currently limited or no treatment options for more information please visit httpwwwatyrpharmacomforwardlooking statementsthis press release contains forwardlooking statements within the meaning of the private litigation reform act  forwardlooking statements are usually identified by the use of words such as anticipates believes estimates expects intends may plans projects seeks should will and variations of such words or similar expressions we intend these forwardlooking statements to be covered by such safe harbor provisions for forwardlooking statements and are making this statement for purposes of complying with those safe harbor provisions these forwardlooking statements including statements regarding the potential of resolaris™ or stalaris™ the ability of the company to undertake certain development activities such as clinical trial enrollment and the conduct of clinical trials and accomplish certain development goals the timing of initiation of additional clinical trials and of reporting results from our clinical trials and reflect our current views about our plans intentions expectations strategies and prospects which are based on the information currently available to us and on assumptions we have made although we believe that our plans intentions expectations strategies and prospects as reflected in or suggested by those forwardlooking statements are reasonable we can give no assurance that the plans intentions expectations or strategies will be attained or achieved furthermore actual results may differ materially from those described in the forwardlooking statements and will be affected by a variety of risks and factors that are beyond our control including without limitation risks associated with the discovery development and regulation of our physiocrinebased product candidates as well as those set forth in our most recent annual report on form k for the year ended december   and in our other sec filings except as required by law we assume no obligation to update publicly any forwardlooking statements whether as a result of new information future events or otherwise  contact mark johnson sr director investor relations mjohnsonatyrpharmacom  to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesatyrpharmaannouncesappointmentofjefferyshatfieldtoitsboardofdirectorshtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextmeg whitmans out will ge chief executive take over ubersiliconbeatthis will be in everyones household by banyan hillsponsoredatt executives to run combined company after time warner dealreuterswind projects in peril as indian states rethink purchasesbloombergamazon surpasses b mark bezos briefly becomes the world’s richest personinvestopediaengineer finds pattern makes millions in stocksmoney morningsponsoredwework raised  million to expand in chinabusiness insider ukthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderhere are the us targets north korea most likely wants to nukebusiness insider mustown stocks in banyan hillsponsoredapnewsbreak yellowstone park cracks down on sex harassmentassociated presschevron and exxon mobil have a tough path ahead nyse traderyahoo finance videostocks mixed after heavy earnings weekhuman barbie takes off make up drs are speechlesskiwi reportsponsoredtrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insiderthe real reason overseas manufacturing is coming to americayahoo financetrump rages at republicans as john mccain kills obamacare repeal billsuzy q trump promised he had a healthcare bill that would lower costs expand coverage and offer more choices where is his bill time to put up or shut upjoin the conversation  k